Company Description
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in the development of antibody-based therapeutics for the treatment of various human diseases in the United States.
The company’s lead product candidates include tovecimig, a bispecific antibody that blocks Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways, which are critical to angiogenesis and tumor vascularization; CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; and CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies.
It also develops CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A; and VEGF-IO Bispecific / Multiple, a bispecific antibody engages the angiogenesis pathway and anti-tumor immune that targets, including immune checkpoints, as well as analyzes VEGF combinations with other immune response-related proteins.
Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.
| Country | United States |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 35 |
| CEO | Thomas Schuetz |
Contact Details
Address: 80 Guest Street, Suite 601 Boston, Massachusetts 02135 United States | |
| Phone | 617 500 8099 |
| Website | compasstherapeutics.com |
Stock Details
| Ticker Symbol | CMPX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001738021 |
| CUSIP Number | 20454B104 |
| ISIN Number | US20454B1044 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Thomas J. Schuetz M.D., Ph.D. | Chief Executive Officer and Vice Chairman |
| Barry Shin J.D., M.B.A. | Chief Financial Officer |
| Jonathan E. Anderman J.D. | Senior Vice President, General Counsel and Corporate Secretary |
| Vered Bisker-Leib MBA, Ph.D. | Advisor |
| Neil L. Lerner CPA | Senior Vice President and Chief Accounting Officer |
| Anna Gifford | Communications Manager |
| Dr. Minori Rosales M.D., Ph.D. | Senior Vice President and Head of Clinical Development |
| Karin Herrera B.A. | Senior Vice President and Head of Clinical Operations |
| Dr. James Kranz Ph.D. | Vice President and Head of Chemistry Manufacturing and Controls |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 16, 2025 | SCHEDULE 13G/A | Filing |
| Jun 12, 2025 | 8-K | Current Report |
| May 15, 2025 | SCHEDULE 13G/A | Filing |
| May 8, 2025 | 10-Q | Quarterly Report |
| May 8, 2025 | 8-K | Current Report |
| Apr 29, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2025 | ARS | Filing |
| Apr 29, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 11, 2025 | SCHEDULE 13D/A | Filing |
| Apr 9, 2025 | 144 | Filing |